ACWActinogen Medical
About Actinogen Medical
Actinogen (ASX:ACW) is a clinical-stage biopharmaceutical company developing innovative treatments for cancer and other diseases. The company's lead product candidate, Xanamem, is a novel small molecule that targets the DNA damage response pathway. Xanamem is currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia. Actinogen is also developing a second product candidate, ACT-701, which is a targeted therapy that is currently in preclinical development for the treatment of solid tumours.
What is ACW known for?
Snapshot
Public AU
Ownership
1999
Year founded
17
Employees
New South Wales, Australia
Head office
1 of 47
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Australia
Produtos e/ou serviços de Actinogen Medical
- Xanamem: A novel small molecule that targets the DNA damage response pathway, currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia.
- ACT-701: A targeted therapy that is currently in preclinical development for the treatment of solid tumours.
- Cognitive impairment in early Alzheimer's Disease: A Phase 2b trial is ongoing to evaluate the efficacy and safety of Xanamem in patients with the early stages of Alzheimer's Disease.
- Cognitive impairment in Major Depressive Disorder: A Phase 2a trial is currently enrolling patients to evaluate the efficacy and safety of Xanamem in patients with Cognitive Impairment and Depressive Disorder.
- Anxiety, sleep & behavioural problems in Fragile X Syndrome: A Phase 2a trial is planned to evaluate the efficacy and safety of Xanamem in patients with Fragile X Syndrome.
- Cortisol Hypothesis: Actinogen is developing therapies that target the cortisol hypothesis, which states that dysregulated brain cortisol plays a role in the development and progression of a variety of neurological diseases.
equipe executiva do Actinogen Medical
- Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.MD, CEO & Director
- Mr. William Edward Souter BCom, IPAA, LLB (Adel)Chief Financial Officer
- Dr. Dana C. Hilt M.D.Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board
- Mr. Andrew B. Udell B.Sc., M.B.A.Chief Commercial Officer
- Mr. Michael RobertsHead of Investor Relations & Corporate Communications
- Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.Head of Clinical Pharmacology & Lead Physician and Depression
- Dr. Fujun Li Ph.D.Head of Manufacturing
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary